MINNEAPOLIS--(BUSINESS WIRE)--March 8, 2006--MGI PHARMA, INC. (Nasdaq:MOGN) today announced the publication of long-term (56 month) follow-up data showing that Gliadel(R) Wafer provides a durable long-term survival benefit for patients with high-grade malignant glioma.
